Antipyrine pharmacokinetics in women receiving conjugated estrogens

The pharmacokinetics of a single 1.0 to 1.2-g intravenous dose of antipyrine was studied in 22 healthy female volunteers aged 28 to 70 years (mean, 45 years). Eleven subjects had been taking a conjugated estrogen preparation for at least 3 months; the other 11 subjects who were not taking conjugated estrogens and who were matched for age, weight, and smoking patterns, served as a control group. Plasma antipyrine concentrations were determined by high-pressure liquid chromatography (HPLC) in multiple plasma samples drawn 24 to 48 hours after dosage. Mean +/- SE pharmacokinetic variables in control and conjugated-estrogen groups were volume of distribution, 0.57 +/- 0.02 versus 0.56 +/- 0.02 L/kg; elimination half-life, 11.0 +/- 0.82 versus 12.6 +/- 0.89 hours; and clearance, 0.63 +/- 0.06 versus 0.54 +/- 0.03 mL/min/kg. None of the differences was significant. Although antipyrine clearance is significantly impaired by oral contraceptives, there is no evidence of altered antipyrine pharmacokinetics from treatment with conjugated estrogens.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				T. Shelepova, A. N. Nafziger, J. Victory, A. D. M. Kashuba, E. Rowland, Y. Zhang, E. Sellers, G. Kearns, J. S. Leeder, A. Gaedigk, et al. Effect of a Triphasic Oral Contraceptive on Drug-Metabolizing Enzyme Activity as Measured by the Validated Cooperstown 5+1 Cocktail J. Clin. Pharmacol., December 1, 2005; 45(12): 1413 - 1421. [Abstract] [Full Text] [PDF]